Security Snapshot

NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) Institutional Ownership

CUSIP: 640268306

13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

170

Shares (Excl. Options)

17,311,411

Price

$42.28

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / COMMON STOCK
Symbol
NKTR on Nasdaq
Shares outstanding
27,358,204
Price per share
$71.95
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
17,311,411
Total reported value
$731,896,489
% of total 13F portfolios
0%
Share change
+2,453,425
Value change
+$83,234,784
Number of holders
170
Price from insider filings
$71.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • NKTR - NEKTAR THERAPEUTICS - COMMON STOCK is tracked under CUSIP 640268306.
  • 170 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 170 to 9 between Q4 2025 and Q1 2026.
  • Reported value moved from $731,896,489 to $1,428,262.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 170 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 640268306?
CUSIP 640268306 identifies NKTR - NEKTAR THERAPEUTICS - COMMON STOCK in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 11% $170,058,594 3,036,761 FMR LLC 27 Feb 2026
BIOTECHNOLOGY VALUE FUND L P 7.4% $32,978,662 1,276,595 BVF PARTNERS L P/IL 01 Jul 2025
VANGUARD GROUP INC 5% +1.2% $43,425,528 +$3,316,543 1,027,089 +8.3% The Vanguard Group 31 Dec 2025
SUSQUEHANNA SECURITIES, LLC 4% -38% $34,245,405 -$18,006,925 809,967 -34% G1 Execution Services, LLC 31 Dec 2025
INTEGRATED CORE STRATEGIES (US) LLC 3% -48% $32,489,559 -$20,590,346 570,994 -39% Millennium Management LLC 30 Sep 2025
Nantahala Capital Management, LLC 2.2% -59% $23,813,902 -$16,571,499 418,522 -41% Nantahala Capital Management, LLC 30 Sep 2025
BlackRock, Inc. 1.6% $5,245,655 203,017 BlackRock, Inc. 30 Jun 2025

As of 31 Dec 2025, 170 institutional investors reported holding 17,311,411 shares of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR). This represents 63% of the company’s total 27,358,204 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) together control 43% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BVF INC/IL 5.7% 1,559,595 +22% 2.2% $65,939,677
VANGUARD GROUP INC 3.8% 1,027,089 +8.3% 0% $43,425,322
Two Seas Capital LP 2.7% 745,185 1.8% $31,506,422
BlackRock, Inc. 2.4% 645,607 +6% 0% $27,296,262
ARMISTICE CAPITAL, LLC 2.2% 596,000 +122% 0.62% $25,198,880
MORGAN STANLEY 2.1% 566,421 -39% 0% $23,948,280
Prosight Management, LP 2% 554,633 4.8% $23,449,883
TWO SIGMA INVESTMENTS, LP 1.7% 473,014 +8.9% 0.03% $19,999,032
Invesco Ltd. 1.7% 468,159 +106% 0% $19,793,774
MILLENNIUM MANAGEMENT LLC 1.7% 454,075 -17% 0.01% $19,198,291
Sofinnova Investments, Inc. 1.6% 438,630 +270% 0.8% $18,545,276
Point72 Asset Management, L.P. 1.6% 433,419 +250% 0.03% $18,324,955
EMERALD ADVISERS, LLC 1.4% 384,342 +19% 0.5% $16,249,980
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.4% 383,310 -59% 0.02% $16,206,346
22NW, LP 1.2% 331,115 0% 11% $13,999,542
Qube Research & Technologies Ltd 1.2% 323,915 +8051% 0.02% $13,695,126
CITADEL ADVISORS LLC 1.1% 309,777 -14% 0.01% $13,097,371
TWO SIGMA ADVISERS, LP 1.1% 308,414 +72% 0.03% $13,039,744
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.1% 295,716 +72% 0.04% $12,502,872
UBS Group AG 1.1% 287,561 +217% 0% $12,158,079
Balyasny Asset Management L.P. 1% 282,021 +54% 0.02% $11,923,848
PRIMECAP MANAGEMENT CO/CA/ 1% 280,150 -3.1% 0.01% $11,844,742
GEODE CAPITAL MANAGEMENT, LLC 0.93% 254,361 +13% 0% $10,757,656
EMERALD MUTUAL FUND ADVISERS TRUST 0.93% 253,125 +8.5% 0.52% $10,702,125
JANE STREET GROUP, LLC 0.8% 218,337 0.01% $9,231,289

Institutional Holders of NEKTAR THERAPEUTICS - COMMON STOCK (NKTR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 19,858 $1,428,262 -$1,198,223 $71.95 9
2025 Q4 17,311,411 $731,896,489 +$83,234,784 $42.28 170
2025 Q3 14,405,809 $819,769,158 +$416,306,829 $56.90 143
2025 Q2 7,657,053 $197,846,106 +$197,839,388 $25.84 100